- 05:51 PM In good spirits: Beam Global bets big on India
- 05:47 PM Trellisys.net: Cashing in on the social networking...
- 05:34 PM Obama asks Americans for patience on economy
- 05:34 PM Italy arrests Pakistanis suspected of Mumbai links
- 04:37 PM Govt plans rice reserve sale in local markets
- 04:22 PM Aurobindo Pharma sees $2 bn sales in next 3 ye...
- 04:07 PM Now, Daigeo's duty free products are under DRI len...
- 03:11 PM RBI's new forex derivative rule too liberal, say e...
- 02:30 PM Implications of tax treaty re-negotiation
- 02:25 PM Beware unearths how agents allegedly sell cars at ...
.jpg)
Karvy Stock Broking has maintained its underperformer rating on Sun Pharmaceutical Industries with a target price of Rs 1125 in its August 17, 2009 research report.
"Sun Pharma recently received USFDA approval for generic Eloxatin and Imitrex. Eloxatin is 180 day shared exclusivity. 5 players have approval during the exclusivity period. We maintain our EPS estimates for FY 10E and FY 11E but upgrade our multiple to 16x as compared to 15x earlier and upgrade our price target by 6.6 % to Rs 1125 based on 16x FY 2011E. We however continue to maintain Underperformer rating on the stock," says Karvy's research report.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
To read the full report click on the attachment......
Attachments : Daily 17-08-09.pdf |
|
Stock Advice
|
|
What's your Opinion |
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- 5 stks that were buzzing last week & how to trade them now
- Buy Aban Offshore, target of Rs 2,200: Anand Rathi
- Buy sugar, financials, pharma on declines: Experts
- Sensex ends over 200 pts up led by banks, oil & gas, metals
- Cox and Kings IPO subscribed 6.31 times
- Bharti Airtel reduces roaming charges to 50 paise/min
- In good spirits: Beam Global bets big on India
Source: CNBC-TV18
- Trellisys.net: Cashing in on the social networking craze
Source: Moneycontrol.com
- Aurobindo Pharma sees $2 bn sales in next 3 years
Source: CNBC-TV18
- Now, Daigeo's duty free products are under DRI lens
Source: Moneycontrol.com
- HDFC Standard Life plans IPO in 2010-11
Source: Business Line
- GM India will not cede ground in Chinese alliance
Source: Business Line
- Spices export rises in Oct
Source: Business Line
- Bharat Hotels to invest Rs 2,300 cr in new properties
Source: Business Line
